Abstract 88P
Background
The WHO Model List of Essential Medicines (EML) serves as guidance for the development of national lists of essential medicines. Since ipilimumab was first approved in 2011, immune checkpoint inhibitors (ICI) have changed the oncologic treatment landscape, leading to significant survival advantages. However, except for malignant melanoma, repeated EML applications of ICIs were unsuccessful and global access remains limited. This study was part of a WHO EML application for the therapeutic class of ICIs in the palliative first-line treatment setting of adult cancers and aims to provide a prioritization framework to select ICIs and indications with the highest potential for EML inclusion.
Methods
After drafting a goal-directed, sequential prioritization plan, the European Medicines Agency’s (EMA) drug database was searched systematically for approved ICI and treatment indications. Next, based on the potential population reach and availability of high-level evidence, ICI-containing treatments approved for the palliative first-line setting were reviewed. Lastly, ESMO-Magnitude of Clinical Benefit Scale (MCBS) scorecards were examined to identify therapeutic indications with a score of 4 or 5, denoting a substantial clinical benefit. ESMO experts will review top-ranked regimens and cancers to complement the evidence about efficacy and harms, judge feasibility and accessibility, and discuss controversial additions.
Results
The EMA drug database search yielded 11 ICIs with 76 different approvals for 21 cancer types and subtypes. Of these, 44 approvals were in the palliative first-line setting. Evaluation against ESMO-MCBS scorecards led to the inclusion of 29 approvals for further evaluation and analysis. Briefing documents for selected cancers and ICIs, with input from ESMO experts, will enhance the transparency and completeness of the EML application to support the WHO Expert committee's selection.
Conclusions
Our research demonstrates the feasibility of using the ESMO-MCBS as part of a framework to identify and prioritise promising ICI-containing treatment regimens for WHO EML application. Therefore, further exploration of the framework as part of the WHO EML application process is warranted.
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
216P - Spatial transcriptomics reveals tumor-microenvironment heterogeneity of breast cancer
Presenter: Hyun Lee
Session: Poster Display session
Resources:
Abstract
217P - Tumor-derived CCL15 regulates RNA m6A methylation in cancer-associated fibroblasts to promote hepatocellular carcinoma growth
Presenter: Yueguo Li
Session: Poster Display session
Resources:
Abstract
218P - A novel tumor adenosine signature to guide indication selection for adenosine pathway inhibitors
Presenter: Sophie Dekoninck
Session: Poster Display session
Resources:
Abstract
219P - Radiotherapy, in conjunction with a PI3Kd/? inhibitor, enhances effector CD8+ T cell-mediated anti-tumor immune responses and the memory function of T cells within the tumor microenvironment by stimulating innate immunity
Presenter: Ye hyun Kim
Session: Poster Display session
Resources:
Abstract
220P - Correlation research between oral flora diversity and radiation-induced stomatitis after postoperative radiotherapy for oral squamous cell carcinoma
Presenter: Qin Zheng
Session: Poster Display session
Resources:
Abstract
221P - Chemoradiotherapy induced adaptive anti-tumor T cell immunity in patients with non-small cell lung cancer
Presenter: Yaoyao Xie
Session: Poster Display session
Resources:
Abstract
222P - Features of epithelial-to-mesenchymal transition (EMT) and humoral immune response in ulcerated acral melanoma: A transcriptomic and spatial proteomic analysis.
Presenter: Estefania Vazquez
Session: Poster Display session
Resources:
Abstract
223P - Frequency of the number of myeloid-derived suppressor cells in patients with lung cancer according to T stage
Presenter: Jelena Vukovic
Session: Poster Display session
Resources:
Abstract
224P - Immunological Dynamics in Triple-Negative Breast Cancer: Peripheral Immune Responses to Neoadjuvant Therapy
Presenter: Rita Santos
Session: Poster Display session
Resources:
Abstract
225P - Assessment of immune cell populations in the peripheral blood of metastatic prostate cancer
Presenter: Vanessa Patel
Session: Poster Display session
Resources:
Abstract